These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 6575696)
1. The abnormal carbohydrate composition of the dysfibrinogenemia associated with liver disease. Martinez J; Keane PM; Gilman PB; Palascak JE Ann N Y Acad Sci; 1983 Jun; 408():388-96. PubMed ID: 6575696 [No Abstract] [Full Text] [Related]
2. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Martinez J; MacDonald KA; Palascak JE Blood; 1983 Jun; 61(6):1196-202. PubMed ID: 6839020 [TBL] [Abstract][Full Text] [Related]
3. Fibrinogen-bound sialic acid levels in the dysfibrinogenaemia of liver disease. Francis JL; Armstrong DJ Haemostasis; 1982; 11(4):215-22. PubMed ID: 6290353 [TBL] [Abstract][Full Text] [Related]
4. Role of sialic acid in acquired dysfibrinogenemia associated with liver cirrhosis. Narvaiza MJ; Fernández J; Cuesta B; Páramo JA; Rocha E Ric Clin Lab; 1986; 16(4):563-8. PubMed ID: 3576054 [TBL] [Abstract][Full Text] [Related]
5. The role of sodium citrate in the dysfibrinogenaemia of liver disease. Francis JL; Watson NJ; Simmonds VJ Thromb Res; 1984 May; 34(3):187-97. PubMed ID: 6729777 [TBL] [Abstract][Full Text] [Related]
6. [Acquired dysfibrinogenemia in a child in the course of a liver disease]. Maak B; Meyer M; Dietze H Monatsschr Kinderheilkd; 1990 Aug; 138(8):446-50. PubMed ID: 2215508 [TBL] [Abstract][Full Text] [Related]
7. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease. Martinez J; Palascak JE; Kwasniak D J Clin Invest; 1978 Feb; 61(2):535-8. PubMed ID: 621288 [TBL] [Abstract][Full Text] [Related]
14. Dysfibrinogenemia associated with hepatoma. Increased carbohydrate content of the fibrinogen molecule. Gralnick HR; Givelber H; Abrams E N Engl J Med; 1978 Aug; 299(5):221-6. PubMed ID: 207986 [TBL] [Abstract][Full Text] [Related]
15. Acquired dysfibrinogenemia following allogeneic bone marrow transplantation. Mori T; Murata M; Wakui M; Muto A; Ishida A; Tanosaki R; Okamoto S; Ikeda Y Am J Hematol; 1997 Dec; 56(4):294-5. PubMed ID: 9395195 [No Abstract] [Full Text] [Related]
16. Fibrin monomers derived from thrombogenic dysfibrinogenemia, Naples-type variant (BβAla68Thr), showed almost entirely normal polymerization. Kamijo T; Nagata K; Taira C; Higuchi Y; Arai S; Okumura N Thromb Res; 2018 Dec; 172():1-3. PubMed ID: 30321757 [No Abstract] [Full Text] [Related]
17. Fibrinogen Šumperk II: dysfibrinogenemia in an individual with two coding mutations. Kotlín R; Suttnar J; Cápová I; Hrachovinová I; Urbánková M; Dyr JE Am J Hematol; 2012 May; 87(5):555-7. PubMed ID: 22407772 [TBL] [Abstract][Full Text] [Related]
18. Fibrinogen Marseille. A new case of congenital dysfibrinogenaemia. Soria J; Soria C; Juhan I; Perrimond H; Haverkate F; Orsini A Haemostasis; 1980; 9(4):214-25. PubMed ID: 7399353 [TBL] [Abstract][Full Text] [Related]
19. Fibrinogen Milano IV, another case of congenital dysfibrinogenemia with an abnormal fibrinopeptide A release (A alpha 16 Arg----His). Bögli C; Hofer A; Baudo F; Redaelli R; Furlan M Haemostasis; 1992; 22(1):7-11. PubMed ID: 1521828 [TBL] [Abstract][Full Text] [Related]